SUNPHARMA to ramp up specialty products portfolio in FY26 to drive growth
SUNPHARMA projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25
#FundamentalViews#WatchOutFor#StockInNews#MacroViews#EquityResearch
200 likes·44 comments

















